Clinical Benefits
The Rabin Cone Contrast Test™ has been shown in over two dozen clinical trials to be one of the most sensitive test for detecting both early and progressive eye disease. It’s sensitivity surpass most structural tests and can identify sub-clinical changes before structural damage is even visible.
The Rabin Cone Contrast Test™ has been proven to identify changes associated with both pre-clinical diabetic eye disease and sub-clinical progression of Intermediate AMD, with no changes visible on the OCT.
The Rabin Cone Contrast Test™ Identifies:
Progression in Intermediate AMD when OCT and fundus photography did not show changes
Changes in diabetics and prediabetes prior to manifest retinopathy
Earliest changes visible in ocular manifestations of multiple sclerosis
Confirmation of pre-glaucomatous damage progression
Duke AMD Longitudinal Clinical Trial
Univ of Houston Pre-diabetes Clinical Trial
Shiga Glaucoma Clinical Trial
UCSF Optic Neuritis Clinical Trial
Practice Benefits
The Rabin Cone Contrast Test™ provides increased revenue, better disease management, improved timing decisions, better outcomes and the opportunity to further build optometry practices.
Increased Revenue
Increased billings
Improved utilization of existing tests
More medical patients
State-of-the-art technology
Attract more medical patients
Better Disease Management
Earlier detection & intervention
Identification of sub-clinical progression
Improved risk assessment
Better Outcomes
Earlier treatment
Improved patient compliance
Demonstrated improvement
Practice Building
Improved Timing Decisions
Prompt treatment plan changes
When to monitor more closely
Optimal timing for referrals